Search Results - "Preti, Robert"

Therapies for rare diseases: therapeutic modalities, progress and challenges ahead by Tambuyzer, Erik, Vandendriessche, Benjamin, Austin, Christopher P., Brooks, Philip J., Larsson, Kristina, Miller Needleman, Katherine I., Valentine, James, Davies, Kay, Groft, Stephen C., Preti, Robert, Oprea, Tudor I., Prunotto, Marco

“…Most rare diseases still lack approved treatments despite major advances in research providing the tools to understand their molecular basis, as well as…”
Get full text

PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI by Quyyumi, Arshed A, Vasquez, Alejandro, Kereiakes, Dean J, Klapholz, Marc, Schaer, Gary L, Abdel-Latif, Ahmed, Frohwein, Stephen, Henry, Timothy D, Schatz, Richard A, Dib, Nabil, Toma, Catalin, Davidson, Charles J, Barsness, Gregory W, Shavelle, David M, Cohen, Martin, Poole, Joseph, Moss, Thomas, Hyde, Pamela, Kanakaraj, Anna Maria, Druker, Vitaly, Chung, Amy, Junge, Candice, Preti, Robert A, Smith, Robin L, Mazzo, David J, Pecora, Andrew, Losordo, Douglas W

“…RATIONALE:Despite direct immediate intervention and therapy, ST-segment–elevation myocardial infarction (STEMI) victims remain at risk for infarct expansion,…”
Get full text

CD34+ cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent by Quyyumi, Arshed A., MD, FRCP, Waller, Edmund K., MD, PhD, Murrow, Jonathan, MD, Esteves, Fabio, MD, Galt, James, PhD, Oshinski, John, PhD, Lerakis, Stamatios, MD, Sher, Salman, MD, Vaughan, Douglas, MD, Perin, Emerson, MD, Willerson, James, MD, Kereiakes, Dean, MD, Gersh, Bernard J., MD, ChB, DPhil, FRCP, Gregory, Douglas, PhD, Werner, Astrid, BS, Moss, Thomas, MD, Chan, Wai Shun, DPhil, Preti, Robert, PhD, Pecora, Andrew L., MD

“…Background The objective of the study was to determine whether the effects of infarct-related artery (IRA) infusion of autologous bone marrow–derived CD34+…”
Get full text

Multi-site evaluation of the BD Stem Cell Enumeration Kit for CD34+ cell enumeration on the BD FACSCanto II and BD FACSCalibur flow cytometers by Preti, Robert A, Chan, Wai Shun, Kurtzberg, Joanne, Dornsife, Ronna E, Wallace, Paul K, Furlage, Rosemary, Lin, Anna, Omana-Zapata, Imelda, Bonig, Halvard, Tonn, Torsten

“…Abstract Background aims Evaluation of the BD Stem Cell Enumeration Kit was conducted at four clinical sites with flow cytometry CD34+ enumeration to assess…”
Get full text

Bringing safe and effective cell therapies to the bedside by Preti, Robert A

Get full text

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab by Goldberg, Stuart L., Pecora, Andrew L., Alter, Robert S., Kroll, Mark S., Rowley, Scott D., Waintraub, Stanley E., Imrit, Kavita, Preti, Robert A.

“…Efforts to reduce relapse of non-Hodgkin lymphoma after autologous transplantation have included ex vivo stem cell selection and/or peritransplantation…”
Get full text

Characterization of mechanical dyssynchrony measured by gated single photon emission computed tomography phase analysis after acute ST-elevation myocardial infarction by Murrow, Jonathan, Esteves, Fabio, Galt, James, Chen, Ji, Garcia, Ernest, Lin, Ji, Lerakis, Stamatios, Sher, Salman, Khan Pohlel, F., Waller, Edmund K., Vaughan, Douglas, Perin, Emerson, Willerson, James, Kereiakes, Dean, Preti, Robert, Pecora, Andrew L., Quyyumi, Arshed A.

“…Left ventricular dyssynchrony is an adverse consequence of ST-elevation myocardial infarction (STEMI) and bears an unfavorable prognosis. Mechanical…”
Get full text

PreSERVE-AMI by Quyyumi Arshed A, Vasquez, Alejandro, Kereiakes Dean J, Klapholz, Marc, Schaer, Gary L, Abdel-Latif, Ahmed, Frohwein, Stephen, Henry, Timothy D, Schatz, Richard A, Dib Nabil, Toma Catalin, Davidson, Charles J, Barsness, Gregory W, Shavelle David M, Cohen, Martin, Poole, Joseph, Moss, Thomas, Hyde, Pamela, Kanakaraj, Anna Maria, Druker Vitaly, Chung, Amy, Junge, Candice, Preti, Robert A, Smith, Robin L, Mazzo, David J, Pecora, Andrew, Losordo, Douglas W

“…Rationale:Despite direct immediate intervention and therapy, ST-segment–elevation myocardial infarction (STEMI) victims remain at risk for infarct expansion,…”
Get full text

Biomanufacturing for clinically advanced cell therapies by Aijaz, Ayesha, Li, Matthew, Smith, David, Khong, Danika, LeBlon, Courtney, Fenton, Owen S., Olabisi, Ronke M., Libutti, Steven, Tischfield, Jay, Maus, Marcela V., Deans, Robert, Barcia, Rita N., Anderson, Daniel G., Ritz, Jerome, Preti, Robert, Parekkadan, Biju

“…The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual…”
Get full text

Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead by Tambuyzer, Erik, Vandendriessche, Benjamin, Austin, Christopher P., Brooks, Philip J., Larsson, Kristina, Needleman, Katherine I. Miller, Valentine, James, Davies, Kay, Groft, Stephen C., Preti, Robert, Oprea, Tudor I., Prunotto, Marco

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Abstract 12754: Infused CD34 Cell Dose, not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients With Left Ventricular Dysfunction post STEMI: Results of the PreSERVE-AMI Trial by Quyyumi, Arshed, Kereiakes, Dean J, Shavelle, David M, Henry, Timothy D, Abdel-Latif, Ahmed, Toma, Catalin, Barsness, Gregory, Frohwein, Steve C, Schatz, Richartd A, Cohen, Martin, Davidson, Charles, Dib, Nabil, Klapholz, Marc, Schaer, Gary L, Vasquez, Alejandro, Moss, Thomas J, Kanakaraj, AnnaMaria, Druker, Vitaly, Harper, Ken, Chung, Amy, Junge, Candice, Preti, Robert, Smith, Robin, Mazzo, David J, Pecora, Andrew, Losordo, Douglas W

“…BackgroundPrior studies suggest an association between naturally high circulating levels of CD34+ cells (CD34) and better outcomes following ischemic events…”
Get full text

ONE YEAR FOLLOW-UP RESULTS FROM PRESERVE-AMI: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF INTRACORONARY INFUSION OF AUTOLOGOUS CD34+ CELLS IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION POST STEMI by Quyyumi, Arshed, Kereiakes, Dean, Shavelle, David, Henry, Timothy, Denktas, Ali, Abdel-Latif, Ahmed, Toma, Catalin, Barsness, Gregory, Frohwein, Stephen, Schatz, Richard, Cohen, Martin, Davidson, Charles, Dib, Nabil, Klapholz, Marc, Schaer, Gary, Vasquez, Alejandro, Pecora, Andrew, Moss, Thomas, Hyde, Pamela, Kanakaraj, Anna Maria, Dich, Le, Druker, Vitaly, Junge, Candice, Preti, Robert, Losordo, Douglas

“…Conclusion: PreSERVE-AMI represents the largest study of cell-based therapy for STEMI completed in US and will determine endpoints, sample size and suitability…”
Get full text

Multisite evaluation of the BD™ Stem Cell Enumeration (SCE) Kit for CD34+ cell enumeration on the BD FACSCanto II™ and BD FACSCalibur™ flow cytometers by Preti, Robert A, Chan, Wai Shun, Kurtzberg, Joanne, Dornsife, Ronna E., Wallace, Paul K., Furlange, Rosemary, Lin, Anna, Omana-Zapata, Imelda, Bonig, Halvard, Tonn, Thorsten

Get full text

Reconstitution of T Cell Subset Repertoire Diversity following Multiple Antigen-Mismatched Bone Marrow Transplantation by Friedman, Thea M., Azhipa, Olga, Zilberberg, Jenny, Tkachuk, Yevgeny, Hsu, Jack W., Rowley, Scott D., Goldberg, Stuart L., Korngold, Robert, Pecora, Andrew L., Preti, Robert A.

Get full text

CD34+CXCR4+ Cell Therapy (AMR-001) for Myocardial Infarction: Preliminary Processing and Product Results of a Phase I Dose Escalation Study by Waller, Ned, Quyyumi, Arshed, Vaughan, Douglas, Moss, Thomas, Chan, Wai S., Preti, Robert, Pecora, Andrew L.

“…Background: Approximately 20% of patients suffering a ST segment elevated acute myocardial infarction (AMI) have progressive peri-infarct zone myocardial cell…”
Get full text

Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: Predictors and clinical relevance by Pecora, Andrew L, Lazarus, Hillard M, Jennis, Andrew A, Preti, Robert A, Goldberg, Stuart L, Rowley, Scott D, Cantwell, Susan, Cooper, Brenda W, Copelan, Edward A, Herzig, Roger H, Meagher, Richard, Kennedy, M.John, Akard, Luke P, Jansen, Jan, Ross, Amy, Prilutskaya, Marina, Glassco, John, Kahn, Douglas, Moss, Thomas J

“…The incidence and clinical relevance of tumor cells contaminating the stem cell products of patients with advanced breast cancer treated with high-dose…”
Get full text

Bone Marrow Derived CD34+CXCR4+ Cells Maintain Viability, Mobility and Sterility up to 72 Hours and Are Compatible with Balloon Dilatation Catheters Used for Intra Coronary Artery Infusion; Pre-Clinical Development of a Pharmaceutical Grade Cell Therapy for Acute Myocardial Infarction (AMR-001) by Pecora, Andrew L., Preti, Robert A., Chan, Wai Shun, Waller, Edmund K., Quyyumi, Arshed, Vaughan, Douglas, Moss, Thomas

“…Background: Approximately 20% of patients suffering a ST segment elevated acute myocardial infarction (AMI) have progressive peri-infarct zone myocardial cell…”
Get full text

Freezing and Cryostorage of Hematopoietic Progenitor Cells (HPC) Apheresis Using 5% Dimethyl Sulfoxide (DMSO) without Hydroxyethyl Starch (HES) in Cryocyte Freezing Bags and in Cryogenic Vials by Chan, Wai Shun, Pecora, Andrew L., Nadasi, Suzi, Myers, Lester, Munoz, Margarita, Jashari, Besa, Preti, Robert A.

“…Cryoprotectant formulated with 5% DMSO, 6% HES, 0.2% dextrose and 3.75% human serum albumin (HSA) [DMSO/(+)HES], originally adapted by Stiff et al ( Blood…”
Get full text

Cryopreservation of Peripheral Blood Stem Cells (PBSC) with Hydroxyethylstarch (HES) and Dimethylsulfoxide (DMSO) Results in Faster Granulocyte Recovery Than Using Dimethylsulfoxide Alone by Chan, Wai Shun, Ma, Michael, Bhatty, Muhammad U.A., Preti, Robert, DeVito, Marie, Pecora, Andrew L., Donato, Michele L., Feldman, Tatyana, Goldberg, Stuart L., Goy, Andre, Siegel, David S., Rowley, Scott D.

“…PBSC components are routinely frozen for storage before autologous transplantation in the treatment of malignant diseases. We have used 5% DMSO, 3.75% human…”
Get full text

Comprehensive Immune Reconstitution without Development of Graft Versus Host Disease (GvHD) Using Limited T-Cell Add Back at the Time of Unrelated Multi-Antigen Mismatched Pan-T-Cell Depleted Transplant by Friedman, Thea M., Hsu, Jack W., Rowley, Scott D., Goldberg, Stuart L., Azhipa, Olga, Zilberberg, Jenny, Tkachuk, Yevgeny, Preti, Robert A., Korngold, Robert, Pecora, Andrew L.

“…Application of unrelated multi-antigen mismatched transplant is limited by a high risk of severe GvHD. Pan-T-Cell depletion successfully limits GvHD in this…”
Get full text